Edition:
United States

Beigene Ltd (BGNE.OQ)

BGNE.OQ on NASDAQ Stock Exchange Global Select Market

131.49USD
17 May 2019
Change (% chg)

$-6.75 (-4.88%)
Prev Close
$138.24
Open
$135.00
Day's High
$137.25
Day's Low
$131.18
Volume
115,779
Avg. Vol
100,092
52-wk High
$220.09
52-wk Low
$105.19

About

BeiGene, Ltd. is principally engaged in biopharmaceutical business. The Company is mainly engaged in the research and development, production and sales of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company's main products include Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and... (more)

Overall

Beta: --
Market Cap(Mil.): $8,091.56
Shares Outstanding(Mil.): 59.80
Dividend: --
Yield (%): --

Financials

  BGNE.OQ Industry Sector
P/E (TTM): -- 101.85 55.51
EPS (TTM): -12.75 -- --
ROI: -42.36 7.41 11.59
ROE: -49.80 7.88 16.33

Earnings vs. Estimates